Top
Summary
All studies
Mortality
Serious outcomes
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
c19early.org COVID-19 treatment researchP2Y12P2Y12 (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

Outcomes in COVID-19 P2Y12 studies

0 0.5 1 1.5+ All studies 19% 1 1,084 Improvement, Studies, Patients Relative Risk Mortality 19% 1 1,084 RCTs 19% 1 1,084 Late 19% 1 1,084 P2Y12 for COVID-19 c19early.org June 2025 FavorsP2Y12 Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ REMAP-CAP Bradbury (RCT) 19% 0.81 [0.67-0.98] death 165/563 170/521 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.022 Late treatment 19% 0.81 [0.67-0.98] 165/563 170/521 19% lower risk All studies 19% 0.81 [0.67-0.98] 165/563 170/521 19% lower risk 1 P2Y12 COVID-19 study c19early.org June 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.022 Effect extraction pre-specified(most serious outcome) Favors P2Y12 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ REMAP-CAP Bradbury (RCT) 19% 0.81 [0.67-0.98] 165/563 170/521 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.022 Late treatment 19% 0.81 [0.67-0.98] 165/563 170/521 19% lower risk All studies 19% 0.81 [0.67-0.98] 165/563 170/521 19% lower risk 1 P2Y12 COVID-19 mortality result c19early.org June 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.022 Favors P2Y12 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ REMAP-CAP Bradbury (RCT) 19% 0.81 [0.67-0.98] death 165/563 170/521 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.022 Late treatment 19% 0.81 [0.67-0.98] 165/563 170/521 19% lower risk All studies 19% 0.81 [0.67-0.98] 165/563 170/521 19% lower risk 1 P2Y12 COVID-19 serious outcome c19early.org June 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.022 Effect extraction pre-specified(most serious outcome) Favors P2Y12 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ REMAP-CAP Bradbury (RCT) 19% 0.81 [0.67-0.98] death 165/563 170/521 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.022 Late treatment 19% 0.81 [0.67-0.98] 165/563 170/521 19% lower risk All studies 19% 0.81 [0.67-0.98] 165/563 170/521 19% lower risk 1 P2Y12 COVID-19 Randomized Controlled Trial c19early.org June 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.022 Effect extraction pre-specified(most serious outcome) Favors P2Y12 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ REMAP-CAP Bradbury (RCT) 19% 0.81 [0.67-0.98] 165/563 170/521 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.022 Late treatment 19% 0.81 [0.67-0.98] 165/563 170/521 19% lower risk All studies 19% 0.81 [0.67-0.98] 165/563 170/521 19% lower risk 1 P2Y12 COVID-19 RCT mortality result c19early.org June 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.022 Favors P2Y12 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ REMAP-CAP Bradbury (RCT) 19% 0.81 [0.67-0.98] death 165/563 170/521 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.022 Late treatment 19% 0.81 [0.67-0.98] 165/563 170/521 19% lower risk All studies 19% 0.81 [0.67-0.98] 165/563 170/521 19% lower risk 1 P2Y12 COVID-19 peer reviewed studies c19early.org June 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.022 Effect extraction pre-specified(most serious outcome) Favors P2Y12 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ REMAP-CAP Bradbury (RCT) 19% 0.81 [0.67-0.98] death 165/563 170/521 Improvement, RR [CI] Treatment Control P2Y12 COVID-19 outcomes c19early.org June 2025 Favors P2Y12 Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit